Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Feb;40(2):126-37.
doi: 10.1016/j.lpm.2010.10.004. Epub 2010 Nov 11.

[Clinical usefulness of circulating ECD/HER-2 measurement for breast cancer patients' management]

[Article in French]
Carole Mathelin  1 , Sabrina Croce, Sébastien Rault, Mouslim Gharbi, Francoise Eichler, Béatrice Gairard, Geneviève Coumaros, Christian Koehl
Affiliations
Review

[Clinical usefulness of circulating ECD/HER-2 measurement for breast cancer patients' management]

[Article in French]
Carole Mathelin et al. Presse Med. 2011 Feb.

Abstract

Background: About 15 to 20% of breast cancer cases overexpress human epidermal growth factor receptor-2 (HER-2). This overexpression is associated with poor clinical prognosis but therapeutic success of trastuzumab or lapatinib. HER-2 extracellular domain (ECD) undergoes a proteolytic cleavage and is shed into biologic fluid as a circulating antigen called ECD/HER-2, which can be detected by immunochemical assays.

Objective: The aim of our review was to determine the clinical usefulness of ECD/HER-2 measurement in the management of breast cancer patients.

Material and methods: A Pubmed search for publications in English or French was carried out until March 31, 2010 (69 original articles and 8 reviews).

Results: The measurement of ECD/HER-2 concentration does not exempt from the pathological determination of HER-2 expression in tumors; some HER-2 negative tumors are associated with high levels of ECD/HER-2, on the other hand, some HER-2 positive tumors present low levels of ECD/HER-2. The concentration of ECD/HER-2 is correlated to disease progression, since 10% of loco-regional breast cancers and more than a third of metastatic breast cancers have high levels of ECD/HER-2. The elevation of ECD/HER-2 levels generally occurs several months before the diagnosis of symptomatic metastases. The relevance of ECD/HER-2 measurements during chemotherapy, hormone therapy and trastuzumab treatment remains uncertain. Similarly, it is not commonly agreed that high levels of ECD/HER-2 before any treatment in the case of an early breast cancer, is an independent prognostic factor.

Discussion: A close analysis of a variety of pathological, biochemical, clinical and methodological data may explain these discrepancies.

Conclusion: New prospective studies using immunochemical measurements of ECD/HER-2 (with a consensual threshold) and based on both detailed pathological analyses and a comprehensive collection of clinical data are still required to establish the clinical usefulness of circulating ECD/HER-2 measurement for breast cancer patients' management.

PubMed Disclaimer